HC Wainwright reissued their buy rating on shares of Pluristem Therapeutics (NASDAQ:PSTI) in a research report report published on Thursday, November 9th. The brokerage currently has a $3.50 target price on the biotechnology company’s stock.
Several other equities research analysts have also recently commented on PSTI. Maxim Group set a $2.00 target price on Pluristem Therapeutics and gave the stock a buy rating in a report on Wednesday, August 16th. ValuEngine cut Pluristem Therapeutics from a sell rating to a strong sell rating in a report on Friday, September 1st. Zacks Investment Research cut Pluristem Therapeutics from a hold rating to a sell rating in a report on Friday, September 22nd. Finally, Seaport Global Securities reaffirmed a buy rating and issued a $5.00 price target on shares of Pluristem Therapeutics in a report on Friday, October 6th. One investment analyst has rated the stock with a sell rating, one has assigned a hold rating and four have issued a buy rating to the stock. The company has a consensus rating of Buy and an average target price of $4.38.
Shares of Pluristem Therapeutics (NASDAQ:PSTI) traded down $0.06 during mid-day trading on Thursday, hitting $1.52. The stock had a trading volume of 219,314 shares, compared to its average volume of 416,764. Pluristem Therapeutics has a fifty-two week low of $1.04 and a fifty-two week high of $2.12.
A number of large investors have recently made changes to their positions in PSTI. Heritage Investors Management Corp acquired a new stake in Pluristem Therapeutics during the 3rd quarter valued at $113,000. Jane Street Group LLC raised its stake in Pluristem Therapeutics by 62.4% during the 1st quarter. Jane Street Group LLC now owns 108,830 shares of the biotechnology company’s stock valued at $134,000 after purchasing an additional 41,796 shares during the period. Psagot Investment House Ltd. grew its holdings in shares of Pluristem Therapeutics by 1,705.2% during the 3rd quarter. Psagot Investment House Ltd. now owns 129,522 shares of the biotechnology company’s stock valued at $196,000 after acquiring an additional 122,347 shares in the last quarter. Finally, Renaissance Technologies LLC grew its holdings in shares of Pluristem Therapeutics by 9.1% during the 1st quarter. Renaissance Technologies LLC now owns 1,553,800 shares of the biotechnology company’s stock valued at $1,911,000 after acquiring an additional 129,000 shares in the last quarter. 4.31% of the stock is currently owned by institutional investors.
ILLEGAL ACTIVITY WARNING: “HC Wainwright Reiterates “Buy” Rating for Pluristem Therapeutics (PSTI)” was originally published by BBNS and is owned by of BBNS. If you are viewing this story on another domain, it was stolen and reposted in violation of US & international copyright and trademark law. The legal version of this story can be read at https://baseballnewssource.com/markets/pluristem-therapeutics-inc-psti-given-buy-rating-at-hc-wainwright/1769812.html.
Pluristem Therapeutics Company Profile
Pluristem Therapeutics Inc is a developer of placenta-based cell therapy product candidates for the treatment of multiple ischemic, inflammatory and hematologic conditions. The Company’s lead indications are critical limb ischemia (CLI), recovery after surgery for femoral neck fracture and acute radiation syndrome.
Receive News & Ratings for Pluristem Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pluristem Therapeutics Inc. and related companies with our FREE daily email newsletter.